Primary Cutaneous Plasmacytoma—Report of Two Cases and Review of the Literature

Wong, K. F.; Chan, John K. C.; Li, L. P.K.; Yau, TK; Lee, A. W.M.

doi:10.1097/00000372-199408000-00006

Cited by 66 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,27 Human cutaneous plasmacytomas are rare and usually solitary; visceral metastases or progression to multiple myeloma is observed in one third of cases. 56,57 Immunohistochemical detection of immunoglobulin heavy and light chains has been the standard test for plasma cell differentiation. 1,4,5,13,29,35,38,42,45 However, nonspecific staining may result from adsorption of immunoglobulins to the cell surface, internalization by phagocytes, or binding of immunoglobulins to a variety of cell types via Fc receptors.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Detection of Multiple Myeloma 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Plasmacytoma: Comparison with CD79a and CD20

2007

View full text Add to dashboard Cite

Abstract. Multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4) is involved in lymphoid cell differentiation, particularly in the production of plasma cells. We examined the immunoreactivity of mouse monoclonal antibody Mum-1p to MUM1/IRF4 and compared it with expression of CD79a and CD20 in 109 plasmacytomas in 107 dogs. Tissues had been fixed in formalin and embedded in paraffin. One hundred one of 109 (93.5%) tumors were positive for MUM1/IRF4. The staining was nuclear with weak cytoplasmic reaction. Fifty-nine of 105 (56.2%) plasmacytomas were positive for CD79a; only 21 of 108 (19.4%) cases were positive for CD20. MUM1/IRF4 staining was performed on 139 other tumors including B-and T-cell lymphomas, histiocytic proliferations, mast cell tumors, and melanocytic tumors. The only MUM1/IRF4-positive nonplasmacytic tumors were 10 B-cell lymphomas and 1 anaplastic lymphoma. We conclude the following: 1) Antibody Mum-1p is very specific for canine plasmacytomas, 2) antibody Mum-1p is superior in sensitivity and specificity to CD79a and CD20 for the identification of canine plasmacytomas in formalin-fixed, paraffin-embedded tissues, 3) canine lymphomas that express MUM1/IRF4 are few and usually of B-cell origin, 4) other canine leukocytic and melanocytic tumors do not express MUM1/IRF4, and 5) prospective studies are needed to determine whether the expression of MUM1/IRF4, particularly in lymphomas, has prognostic significance.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Detection of Multiple Myeloma 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Plasmacytoma: Comparison with CD79a and CD20

2007

View full text Add to dashboard Cite

show abstract

“…A variety of other sites can rarely be involved, including testis, bladder, urethra, breast, ovary, lung, pleura, thyroid, orbit, brain, skin, adrenal glands, retroperitoneum, central nervous system, spleen and the lymph nodes (Cavanna et al, 1990;Rubin et al, 1990;Matsumiyama et al, 1992;Nonamura et al, 1992;Wong et al, 1994;Adkins et al, 1996;Fischer et al, 1996;Tuting & Bork, 1996 A monoclonal paraprotein is detected in the serum and/or urine in fewer than 25% of patients (Table 1). Local recurrence rates of <5% have been quoted after radiotherapy .…”

Section: Epidemiology and Clinically-laboratory Featuresmentioning

confidence: 99%

Solitary Bone and Extramedullary Plasmacytoma

Salogub¹,

Lokhmatova²,

Sozin³

2012

Multiple Myeloma - An Overview

View full text Add to dashboard Cite

“…In general, authors agreed that curative-intent local treatment-which can entail surgery, rt, or surgery followed by adjuvant rt-is appropriate for solitary pcp lesions 1,9,23,31,46 . Green et al 68 cautioned that local recurrence or lymph node metastases could develop after local therapy.…”

Section: Discussionmentioning

confidence: 99%